Press Releases

Summary Toggle Chembio Diagnostics Submits EUA Application for DPP SARS-CoV-2 Antigen Test System

Oct 15, 2020

Rapid Test Provides Results in Only 20 Minutes HAUPPAUGE, N.Y. , Oct. 15, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the submission of an application for Emergency Use Authorization
Read more

PDF Version
Summary Toggle Chembio Diagnostics Receives FDA Approval for DPP HIV-Syphilis System

Oct 2, 2020

First Rapid Test Approved in U.S. to Aid in Diagnosis of Both HIV and Syphilis from Single Patient Sample HAUPPAUGE, N.Y. , Oct. 02, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that the
Read more

PDF Version
Summary Toggle Chembio Submits EUA Application for New DPP SARS-CoV-2 IgM/IgG Test System

Sep 8, 2020

New Antibody Test System Provides Results in 15 Minutes from Finger Stick, Venous Whole Blood, Plasma, or Serum Samples HAUPPAUGE, N.Y. , Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today
Read more

PDF Version
Summary Toggle Chembio Diagnostics Reports Second Quarter 2020 Financial Results

Aug 6, 2020

HAUPPAUGE, N.Y. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended June 30, 2020 . Recent Accomplishments & Highlights Announced plans to
Read more

PDF Version
Summary Toggle Chembio Diagnostics to Report Second Quarter 2020 Financial Results on August 6, 2020

Jul 23, 2020

HAUPPAUGE, N.Y. , July 23, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter 2020 after the close of trading on Thursday, August
Read more

PDF Version
Summary Toggle Chembio Diagnostics Announces Preliminary Estimates of Second Quarter 2020 Revenues

Jul 6, 2020

Company to Host Conference Call Tuesday, July 7 HAUPPAUGE, N.Y. , July 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics , Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced its preliminary estimates of revenue results for the
Read more

PDF Version
Summary Toggle Chembio Announces Plans to Seek EUA Approval from FDA for Revised DPP COVID-19 IgM/IgG System and New DPP COVID-19 Antigen System

Jul 6, 2020

HAUPPAUGE, N.Y. , July 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics , Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced its plans to submit applications to the U.S. Food and Drug Administration (FDA) for Emergency Use
Read more

PDF Version
Summary Toggle Chembio Diagnostics Awarded BARDA Contract for Development of DPP COVID-19 Point-of-Care Antigen System

Jul 6, 2020

HAUPPAUGE, N.Y. , July 06, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), part of
Read more

PDF Version
Summary Toggle Chembio to Report COVID-19 Product Development Plans and Preliminary Estimated Second Quarter 2020 Revenue Results

Jul 1, 2020

Press Releases to be Issued on July 6, and Conference Call to be Held on July 7 HAUPPAUGE, N.Y. , July 01, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics , Inc. (Nasdaq: CEMI), a leading global point-of-care diagnostic company focused on infectious diseases, today announced today that it will issue,
Read more

PDF Version
Summary Toggle Chembio Diagnostics Receives FDA 510(k) Clearance for DPP Zika IgM System

Jun 8, 2020

HAUPPAUGE, N.Y. , June 08, 2020 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the DPP Zika IgM System.
Read more

PDF Version